| Literature DB >> 27980789 |
Muriel N Maeder1, Henintsoa M Rabezanahary1, Norosoa J Zafindraibe1, Martin Raoelina Randriatiana2, Tahinamandranto Rasamoelina3, Andry T Rakotoarivo4, Philippe Vanhems5, Jonathan Hoffmann6, Thomas Bénet5, Mala Rakoto Andrianarivelo1, Olivat A Rakoto-Alson7.
Abstract
BACKGROUND: In Madagascar, the last study on sickle cell disease (SCD) was done in the early 1980s. The country is known as endemic for malaria and respiratory infections. The main objective of this study was to estimate the prevalence of SCD; the secondary objective was to evaluate its association with malaria and respiratory infections.Entities:
Keywords: Children; Fever; Madagascar; Malaria; Respiratory Infections; Sickle-cell disease
Year: 2016 PMID: 27980789 PMCID: PMC5134128 DOI: 10.1186/s12878-016-0069-1
Source DB: PubMed Journal: BMC Hematol ISSN: 2052-1839
Characteristics of study population by haemoglobin phenotype
| Characteristics | HbAA ( | HbAS ( | HbSS ( |
|
|---|---|---|---|---|
| Period, quarter, N (%) | ||||
| - January-March | 72 (12.1) | 31 (16.1) | 3 (15.8) | 0.19 |
| - April-June | 195 (32.7) | 57 (29.7) | 7 (36.8) | |
| - July-September | 135 (22.6) | 54 (28.1) | 6 (31.6) | |
| - October-December | 194 (32.5) | 50 (26.0) | 3 (15.8) | |
| Age, months, median (IQR) | 21.0 (10.5–36.0) | 20.0 (9.0–36.5) | 17.0 (10.0–33.0) | 0.50 |
| Age category, months, n (%) | ||||
| - 2–11 | 160 (26.8) | 62 (32.3) | 6 (31.6) | 0.68 |
| - 12–23 | 152 (25.5) | 45 (23.4) | 5 (26.3) | |
| - 24–59 | 284 (47.7) | 85 (44.3) | 8 (42.1) | |
| Gender, n (%) | ||||
| - Male | 306 (51.3) | 82 (42.7) | 13 (68.4) | 0.03 |
| - Female | 290 (48.7) | 110 (57.3) | 6 (31.6) | |
| Temperature, °C, median (IQR) | 38.8 (38.6–39.4) | 38.8 (38.6–39.4) | 38.5 (38.0–38.7) | 0.11 |
| Height, cm, median (IQR) | 78.0 (71.0–87.0) | 77.0 (69.5–86.0) | 74.0 (69.0–86.0) | 0.18 |
| Weight, kg, median (IQR) | 9.5 (8.1–11.6) | 9.3 (7.9–11.4) | 8.5 (7.2–10.0) | 0.61 |
| Mid-upper arm circumference, cm, median (IQR) | 140 (133–146) | 140 (132–148) | 128 (117–136) | 0.001 |
| Weight-for-height Z-score ≤2 SD | −1.5 (−2.2; −0.7) | −1.2 (−2.2; −0.5) | −2.2 (−3.4; −1.2) | 0.02 |
| Positive RDT malaria, n (%) | 227 (38.1) | 63 (32.8) | 5 (26.3) | 0.3 |
| Naso-pharyngeal carriers positive detection, n (%) | ||||
| - Parechovirus | 9 (1.6) | 1 (0.6) | 2 (11.1) | 0.02 |
| - RSV A and B | 56 (9.8) | 30 (17.0) | 0 (0) | 0.01 |
| - Human coronavirus 229E | 6 (1.1) | 0 (0) | 1 (5.6) | 0.07 |
| - Viral coinfection | 144 (25.3) | 34 (19.2) | 8 (44.4) | 0.03 |
|
| 11 (1.9) | 3 (1.6) | 1 (5.3) | 0.5 |
* HbAA, normal phenotype, HbAS sickle cell trait, HbSS sickle cell disease
Fig. 1Prevalence of malaria-infected children by age group and haemoglobin status
Fig. 2Viral respiratory and atypical bacteria pathogens detected in the nasopharyngeal swabs of study children according to haemoglobin phenotype. HRV: human rhinovirus; HAdV: human adenovirus; HBoV: human bocavirus; RSV: respiratory syncytial virus A and B; hPIV: human parainfluenzavirus 1, 2, 3 or 4; hMPV: human metapneumovirus A or B; HCoV: human coronaviruses NL63, 229E, OC43 or HKU1; HEV: enterovirus; FLU: influenza viruses A, B or A (H1N1)/pdm09; HPeV: human parechovirus; Cpneu: Chlamydia pneumoniae; Mpneu: Mycoplasma pneumoniae
Microbiological findings associated with heamoglobin status, univariate polytomous logistic regression
| Microorganism | Heterozygous form HbAS ( | Homozygous form HbSS ( | ||
|---|---|---|---|---|
| Crude odds ratio (95% CI)* |
| Crude odds ratio (95% CI)* |
| |
| > = 1 bacteria from blood | 0.8 (0.4–2.0) | 0.7 | 3.8 (1.04–14.2) | 0.04 |
| > = 1 bacteria from respiratory sample | 1.2 (0.6–2.2) | 0.62 | NE | – |
| > = 1 virus from respiratory sample | 0.9 (0.6–1.3) | 0.57 | 0.5 (0.2–1.3) | 0.15 |
| Coinfection from respiratory sample | 0.9 (0.6–1.3) | 0.65 | 0.7 (0.3–1.8) | 0.44 |
| Viral coinfection from respiratory sample | 0.7 (0.5–1.1) | 0.1 | 2.4 (0.9–6.1) | 0.08 |
| Blood | ||||
|
| 0.8 (0.2–3.1) | 0.8 | 3.0 (0.4–24.1) | 0.31 |
|
| 0.8 (0.2–3.1) | 0.8 | 3.0 (0.4–24.1) | 0.31 |
|
| 0.4 (0.05–3.6) | 0.44 | 4.7 (0.5–40.0) | 0.16 |
| Respiratory sample | ||||
|
| 1.2 (0.7–2.0) | 0.56 | NE | – |
|
| 1.6 (0.9–2.9) | 0.14 | 1.9 (0.4–8.4) | 0.42 |
|
| 1.0 (0.6–1.7) | 0.85 | 0.4 (0.05–3.0) | 0.37 |
|
| 0.6 (0.07–5.5) | 0.68 | NE | − |
|
| 2.3 (0.7–7.4) | 0.15 | NE | − |
| Respiratory syncytial virus A and B | 1.9 (1.2–3.0) | 0.01 | NE | − |
| Human metapneumovirus A and B | 0.6 (0.3–1.1) | 0.11 | NE | − |
| Human rhinovirus | 1.0 (0.7–1.5) | 0.9 | 1.8 (0.6–4.8) | 0.27 |
| Human parainfluenzavirus 1 | 0.9 (0.4–2.0) | 0.73 | NE | − |
| Human parainfluenzavirus 2 | 1.2 (0.4–3.5) | 0.68 | NE | − |
| Human parainfluenzavirus 3 | 1.2 (0.5–2.9) | 0.7 | 1.7 (0.2–13.5) | 0.6 |
| Human parainfluenzavirus 4 | 0.5 (0.06–4.5) | 0.56 | NE | − |
| Human coronavirus 229E | NE | − | 5.5 (0.6–48.4) | 0.12 |
| Human coronavirus NL63 | 1.2 (0.4–3.2) | 0.79 | NE | − |
| Human coronavirus OC43 | 0.5 (0.2–1.4) | 0.21 | 1.1 (0.1–8.5) | 0.93 |
| Human coronavirus HKU1 | 1.2 (0.3–4.6) | 0.78 | NE | − |
| Influenza virus A | NE | − | NE | − |
| Influenza virus A (H1N1)/pdm09 | 0.2 (0.03–1.7) | 0.15 | 2.3 (0.3–18.8) | 0.43 |
| Influenza virus B | 0.9 (0.4–2.2) | 0.88 | NE | − |
| Human parechovirus | 0.4 (0.04–2.8) | 0.32 | 7.8 (1.6–38.9) | 0.01 |
| Human adenovirus | 1.0 (0.6 (1.7) | 0.94 | 1.8 (0.6–5.5) | 0.32 |
| Human bocavirus | 0.7 (0.4–1.3) | 0.24 | 1.4 (0.4–5.0) | 0.58 |
| Enterovirus | 0.5 (0.2–1.1) | 0.09 | 0.7 (0.09–5.4) | 0.73 |
*After polytomous univariate logistic regression, compared with normal form HbAA (n = 569)
NE, non estimable